Speciality
Spotlight

 




 


Genetics


    

 





Congenital Malformation Diagnosis

    

  • UK Multicentre Project on Assessment of Risk of Trisomy 21 by Maternal Age and Fetal Nuchal-Translucency Thickness at 10-14 Weeks of Gestation

    Snijders RJM, for the Fetal Medicine Foundation First Trimester Screening Group (King’s Collelge School of Medicine, London)

    Lancet 351-343-346-1998

      


    Prenatal screening for trisomy 21 involves invasive procedures for those considered at high risk because of maternal age. A newer method of prenatal screening involves a combination of maternal age and measurement of the subcutaneous edema of the fetal neck, visualized by US as nuchal translucency. A multicenter study was performed in the United Kingdom to evaluate screening for trisomy 21 with a combination of maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation in 96,127 pregnancies from 22 centers in the United Kingdom.

       


    Conclusions This continuing multicenter study demonstrated that prenatal screening for trisomy 21 can be performed effectively and noninvasively during the first trimester with a combination of maternal age and fetal nuchal-translucency thickness on ultrasonograms. The sensitivity of this screening protocol is approximately 80%. However, because the incidence of trisomy 21 is low, it still takes approximately 30 invasive tests to identify 1 affected fetus. Increased
    nuchal-translucency

    thickness can also be used for the prenatal identification of many other chromosomal abnormalities.

       

 



 

 

Speciality Spotlight

 

 
Genetics
    

 

Congenital Malformation Diagnosis
    

  • UK Multicentre Project on Assessment of Risk of Trisomy 21 by Maternal Age and Fetal Nuchal-Translucency Thickness at 10-14 Weeks of Gestation Snijders RJM, for the Fetal Medicine Foundation First Trimester Screening Group (King’s Collelge School of Medicine, London)
    Lancet 351-343-346-1998
      
    Prenatal screening for trisomy 21 involves invasive procedures for those considered at high risk because of maternal age. A newer method of prenatal screening involves a combination of maternal age and measurement of the subcutaneous edema of the fetal neck, visualized by US as nuchal translucency. A multicenter study was performed in the United Kingdom to evaluate screening for trisomy 21 with a combination of maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation in 96,127 pregnancies from 22 centers in the United Kingdom.
       
    Conclusions This continuing multicenter study demonstrated that prenatal screening for trisomy 21 can be performed effectively and noninvasively during the first trimester with a combination of maternal age and fetal nuchal-translucency thickness on ultrasonograms. The sensitivity of this screening protocol is approximately 80%. However, because the incidence of trisomy 21 is low, it still takes approximately 30 invasive tests to identify 1 affected fetus. Increased nuchal-translucency
    thickness can also be used for the prenatal identification of many other chromosomal abnormalities.
       

 

 

By |2022-07-20T16:41:55+00:00July 20, 2022|Uncategorized|Comments Off on Congenital Malformation Diagnosis

About the Author: